Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective

Nature Reviews Drug Discovery

Volumn 3, Issue 9, 2004, Pages 763-769

  Lesko, Lawrence J ^a   Woodcock, Janet ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; AZATHIOPRINE; CYTOCHROME P450 2C9; GEFITINIB; GLUCURONOSYLTRANSFERASE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; PROTEIN TYROSINE KINASE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; DNA SEQUENCE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUSTRY; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC CODE; HAPLOTYPE; HUMAN; INSOMNIA; IRRITABILITY; LABORATORY TEST; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

DRUG APPROVAL; DRUG DESIGN; HUMANS; PHARMACOGENETICS; RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 4544335467     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1499     Document Type: Article

References (11)

1. DiMasi, J., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
2. Gilbert, J. Rebuilding big PhRMA's business model. In Vivo November, 73-80 (2003).
3. Tufts CDSS quantifies savings from boosting new drug R&D efficiency. Tufts CSDD Impact Peport 4, 1-4 (2002).
4. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Eng. J. Med. 350, 2129-2139 (2004).
5. Guillermo Paez, J. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib. Science 304, 1497-1500 (2004).
6. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products [online], http://www,fda.gov/oc/initiatives/criticalpath/whitepaper.html (2004).
7. Lesko, L. J. & Woodcock, J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2, 20-24 (2002).
8. Lesko, L. J. et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PHRMA-DRUSAFE workshop. J. Clin. Pharmacol. 43, 342-358 (2003).
9. Salerno, R. A. & Lesko, L. J. Pharmacogenomics in drug development and regulatory decision-making: the genomic data submission (GDS) proposal. Pharmacogenomics 5, 25-30 (2004).
10. Salerno, R. A. & Lesko, L. J. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5, 503-505 (2004).
11. Peck, C. C., Temple, R. T & Collins, J. Understanding consequences of concurrent therapies. JAMA 269, 1513-1518 (1993).